Spots Global Cancer Trial Database for folfiri.3
Every month we try and update this database with for folfiri.3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | NCT02827201 | Metastatic Panc... | FOLFIRI.3 nab-paclitaxel+... | 18 Years - 75 Years | Federation Francophone de Cancerologie Digestive | |
FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | NCT02827201 | Metastatic Panc... | FOLFIRI.3 nab-paclitaxel+... | 18 Years - 75 Years | Federation Francophone de Cancerologie Digestive | |
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer | NCT00786006 | Metastatic Panc... | FOLFIRI.3 FOLFOX | 18 Years - | Asan Medical Center | |
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer | NCT00786006 | Metastatic Panc... | FOLFIRI.3 FOLFOX | 18 Years - | Asan Medical Center | |
FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | NCT02827201 | Metastatic Panc... | FOLFIRI.3 nab-paclitaxel+... | 18 Years - 75 Years | Federation Francophone de Cancerologie Digestive | |
First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem | NCT02352337 | Metastatic Panc... | FOLFIRINOX LV5FU2 FOLFIRI.3 Gemcitabine | 18 Years - | Federation Francophone de Cancerologie Digestive |